IL15 and neoplasm: Some pro-inflammatory cytokines (e.g., IL-12, IL-23, IL-15) armed oncolytic VACVs showed stronger anti-tumor immune response by enhancing T-cell and NK cell activation and cytotoxicity in addition to increasing the production of IFN-γ (62–64).